» Articles » PMID: 23922463

Clinical Utility of Anti-p53 Auto-antibody: Systematic Review and Focus on Colorectal Cancer

Overview
Specialty Gastroenterology
Date 2013 Aug 8
PMID 23922463
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Mutation of the p53 gene is a key event in the carcinogenesis of many different types of tumours. These can occur throughout the length of the p53 gene. Anti-p53 auto-antibodies are commonly produced in response to these p53 mutations. This review firstly describes the various mechanisms of p53 dysfunction and their association with subsequent carcinogenesis. Following this, the mechanisms of induction of anti-p53 auto-antibody production are shown, with various hypotheses for the discrepancies between the presence of p53 mutation and the presence/absence of anti-p53 auto-antibodies. A systematic review was performed with a descriptive summary of key findings of each anti-p53 auto-antibody study in all cancers published in the last 30 years. Using this, the cumulative frequency of anti-p53 auto-antibody in each cancer type is calculated and then compared with the incidence of p53 mutation in each cancer to provide the largest sample calculation and correlation between mutation and anti-p53 auto-antibody published to date. Finally, the review focuses on the data of anti-p53 auto-antibody in colorectal cancer studies, and discusses future strategies including the potentially promising role using anti-p53 auto-antibody presence in screening and surveillance.

Citing Articles

Novel combined tumor autoantibody detection in serological diagnosis of gastric cancer.

Yu Z, Zhang H, Li S, Huo Q, Ling H, Chen K Int J Clin Exp Pathol. 2025; 18(1):23-29.

PMID: 39949595 PMC: 11815391. DOI: 10.62347/XMAW3065.


Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.

Montero-Calle A, Garranzo-Asensio M, Moreno-Casbas M, Campuzano S, Barderas R Front Immunol. 2024; 15:1455602.

PMID: 39234247 PMC: 11371560. DOI: 10.3389/fimmu.2024.1455602.


Serum BRD2 autoantibody in hepatocellular carcinoma and its detection using mimotope peptide‑conjugated BSA.

Heo C, Lim W, Park I, Choi Y, Lim K, Cho E Int J Oncol. 2022; 61(6).

PMID: 36321789 PMC: 9635863. DOI: 10.3892/ijo.2022.5448.


Comparison between a new assay system, Elecsys Anti-p53, and conventional MESACUP™ for the detection of serum anti-p53 antibodies: A multi-institutional study.

Suzuki T, Oshima Y, Shiratori F, Nanami T, Yajima S, Sumazaki M Mol Clin Oncol. 2022; 17(2):130.

PMID: 35832468 PMC: 9264320. DOI: 10.3892/mco.2022.2563.


Prospective Proteomic Study Identifies Potential Circulating Protein Biomarkers for Colorectal Cancer Risk.

Sun X, Shu X, Lan Q, Laszkowska M, Cai Q, Rothman N Cancers (Basel). 2022; 14(13).

PMID: 35805033 PMC: 9265260. DOI: 10.3390/cancers14133261.


References
1.
Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D . Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepatogastroenterology. 2007; 54(77):1422-5. View

2.
Porrini R, Vercellino V, Rocchetti V, Reno F, Giorda E, Pomato E . Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions. Minerva Stomatol. 2010; 59(5):233-9, 239-43. View

3.
Saleh J, Kreissler-Haag D, Montenarh M . p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- or C-terminus of p53. Int J Oncol. 2004; 25(4):1149-55. View

4.
Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M . Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci. 2000; 45(1):122-8. DOI: 10.1023/a:1005473729976. View

5.
Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View